Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

David Baker, Milan Bimali, PhD, Luis Carrillo, MD, Archana Sachedina, Daisy Alapat, MD, Md shadiqul Hoque, MD, Mathew Kottarathara, MD, Richa Parikh, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138877

Published: 2020

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells

Erming Tian, PhD MBA, Jeffery R. Sawyer, Ricky D. Edmondson, Maurizio Zangari, MD, Christopher P. Wardell, PhD MSc, BSc, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4390.

https://doi.org/10.1182/blood-2019-131850

Published: 2019

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Eileen M Boyle, MD MSc, Faith E. Davies, MD, Shayu Deshpande, Ruslana G. Tytarenko, MS, Cody Ashby, PhD, Yan Wang, Christopher P. Wardell, PhD MSc, BSc, Michael A Bauer, PhD, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Louis Williams, MD MBA, Thierry Facon, MD, Charles Dumontet, Bart Barlogie, MD PhD, Gareth Morgan, MDPhDFRCP, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 4333.

https://doi.org/10.1182/blood-2019-126679

Published: 2019

Journal Articles

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

Blood (2018) 132 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2018-99-119249

Published: 2018

Journal Articles

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 408.

https://doi.org/10.1182/blood-2018-99-117359

Published: 2018

Journal Articles

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Cody Ashby, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2018-99-116455

Published: 2018

Journal Articles

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Michael A Bauer, PhD, Matthew Henry, M.S., Purvi Patel, Yan Wang, Joshua Epstein, DSc, Faith E. Davies, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD, Sarah K Johnson, PhD

Blood (2018) 132 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2018-99-119131

Published: 2018

Journal Articles

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Tarun K. Garg, PhD, Katie Stone, BS, Hongwei Wang, MS, Antje Hoering, PhD, Brian A Walker, PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Faith E. Davies, MD, Gareth Morgan, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2018-99-119692

Published: 2018

Journal Articles

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

Leo Rasche, Manoj Kumar, MD, Grant Gershner, James E McDonald, BS, MD, Samrat Roy Choudhury, PhD, Rudy L. Van Hemert, MD, Joshua Epstein, DSc, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth Morgan, MD, Niels Weinhold, PhD

Blood (2018) 132 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2018-99-119759

Published: 2018

Journal Articles

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Joshua Epstein, DSc, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Faith E. Davies, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2018-99-115090

Published: 2018

Journal Articles

Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53

Cody Ashby, PhD, Yan Wang, Ruslana G. Tytarenko, MS, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Jeffery R. Sawyer, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4441.

https://doi.org/10.1182/blood-2018-99-113102

Published: 2018

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Eileen M Boyle, MD MSc, Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Yan Wang, Michael A Bauer, PhD, Shayu Deshpande, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Christopher Wardell, PhD, Niels Weinhold, PhD, Thierry Facon, Charles Dumontet, Gareth Morgan, MD, Faith E. Davies, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2018-99-117193

Published: 2018

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

The Mutational Landscape of Primary Plasma Cell Leukemia

Carolina D. Schinke, MD, Cody Ashby, PhD, Yan Wang, Ruslana G. Tytarenko, MS, Eileen Boyle, Christopher Wardell, PhD, Pingping Qu, Sharmilan Thanendrarajan, MD, Sandra Susanibar, MD, Naveen Yarlagadda, MD, Maliha Khan, Meera Mohan, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Bart Barlogie, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 114.

https://doi.org/10.1182/blood-2018-99-116758

Published: 2018

NARROW

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

The Mutational Landscape of Primary Plasma Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only